Multiple sclerosis

Handbook of Clinical Neuroepidemiology

Volumn , Issue , 2007, Pages 557-572

  Román, Gustavo C ^a   Castellanos Mateus, Patricia ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 64449087700     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (78)

1. Pryse-Phillips W. Companion to Clinical Neurology. Second Edition, Oxford: Oxford University Press, 2003.
2. Lensch E, Matzke M, Petereit H-F, Scherer P, Schramm S, Calabrese P. Identification and management of cognitive disorders in multiple sclerosis--a consensus approach. J Neurol 2006;253(Suppl 1):I29-31.
3. Poser CM. Multiple sclerosis. Observations and reflections-a personal memoir. J Neurol Sci 1992;107:127-140.
4. Poser CM, Brinar VV. The nature of multiple sclerosis. Clin Neurol Neurosurg 2004;106: 159-171.
5. Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: Report by the Panel on the Evaluation of Experimental Trials of Therapy in Multiple Sclerosis. Ann NY Acad Sci 1965;122:552-568.
6. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227-231.
7. McDonald WI, Compston DAS, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127.
8. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-2069.
9. Tintore M, Rovira A, Martinez M, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000;21:702-706.
10. Weiner HL. A 21 point unifying hypothesis on the etiology and treatment of multiple sclerosis. Can J Neurol Sci 1998;25:93-101.
11. Frohman EM, Racke MK, Raine CS. Multiple sclerosis--the plaque and its pathogenesis. N Engl J Med 2006;354:942-955.
12. Kuhlmann T, Lingfeld G, Bitsch A, et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002;125: 2202-2212.
13. Kutzke JF: Epidemiology and etiology of multiple sclerosis. Phys Med Rehabil Clin N Am 2005;16:327-349.
14. Marrie RA. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurology 2004;3:709-718.
15. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci 2001;22: 117-139.
16. Zavadinov R, Iona R, Monti-Bragadin L, et al. The use of standardized incidence and prevalence rates in epidemiological studies on multiple sclerosis. A meta-analysis study. Neuroepidemiology 2003;22:65-74.
17. Landtblom AM, Riise T, Boiko A, Söderfeldt B. Distribution of multiple sclerosis in Sweden based on mortality and disability compensation statistics. Neuroepidemiology 2002;21:167-179.
18. Landtblom AM, Riise T, Kurtzke JF. Further considerations on the distribution of multiple sclerosis in Sweden. Acta Neurol Scand 2005;111:238-246.
19. Callender M, Landtblom A-M. A cluster of multiple sclerosis cases in Lysvik in the Swedish county of Varmland. Acta Neurol Scand 2004;110:14-22
20. Pugliatti M, Riise T, Sotgiu MA, et al. Increasing incidence of multiple sclerosis in the province of Sassari, northern Sardinia. Neuroepidemiology 2005;25:129-134.
21. Dean G, Elian M, de Bono AG, et al. Multiple sclerosis in Malta in 1999: an update. J Neurol Neurosurg Psychiatry 2002;73:256-260.
22. Hader WJ. The incidence and prevalence of multiple sclerosis in Saskatoon, Saskatchewan: A reappraisal. Neuroepidemiology 1999;18:331.
23. Beck CA, Metz LM, Stevenson LW, Patten SB. Regional variation of multiple sclerosis prevalence in Canada. Mult Scler 2005;11:516-519.
24. Hader WJ, et al. The occurrence of multiple sclerosis in the Hutterites of North America. Can J Neurol Sci 1996;23:291-295.
25. Baum HM, Rothschild BB. The incidence and prevalence of reported multiple sclerosis. Ann Neurol 1981;10:420-428.
26. Wallin MT, Page WF, Kurtzke JF. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann Neurol 2004;55:65-71.
27. Redelings MD, McCoy L, Sorvillo F. Multiple sclerosis mortality and patterns of comorbidity in the United States from 1990 to 2001. Neuroepidemiology 2006;26:102-107.
28. Corona T, Román GC. Multiple sclerosis in Latin America. Neuroepidemiology 2006;26:1-3.
29. Alter M, Olivares O. Multiple sclerosis in México. Arch Neurol 1970:23;451-459.
30. Velázquez M, Macias MA, Rivera OV, Lozano Z. Grupo Mexicano de estudio de la esclerosis múltiple. Rev Neurol 2003; 36: 1019-1022.
31. Corona T, Rodríguez LJ, Otero E, Stopp L. Multiple sclerosis in México: hospital cases at the National Institute of Neurology and Neurosurgery. Neurología 1996;11:170-173.
32. Corona T, Ruiz JL, Arriada N. Optic neuritis progressing to multiple sclerosis. Acta Neurol Scand 1997;95;85-89.
33. Lazo M, Corona T. Neuritis óptica: seguimiento a largo plazo en población mexicana. Rev Neurol 2002;35:1190.
34. Cristiano E, Patrucco L, Garcea O, et al. Prevalence of multiple sclerosis (MS) in Argentina using the capture-recapture method. Neurology 1999; 2(suppl):A438.
35. Piedrabuena R, Giobellina R, Alvarez D, Abatedaga V. High prevalence of multiple sclerosis in the city of Oliva, Cordoba, Argentina. Arq Neuropsiquiatr 2004; 62: 13.
36. Papais-Alvarenga R, Alves S, Miranda C, et al. Characteristics of multiple sclerosis in Brazil: multicentric study in a prevalence cohort - South Atlantic project phase 1. J Neurol Sci 1997;150:S229.
37. Gama P, Trigo L, Andrade R, Sala C, on behalf of the Brazilian Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS). Epidemiological study of multiple sclerosis in the city of Sorocaba, Brazil. Arq Neuropsiquiatr 2004;62:13.
38. Callegaro D, Godbaum M, Morais L, et al. The prevalence of multiple sclerosis in the city of Sao Paulo, Brazil. Acta Neurol Scand 2001:104: 2208-2137.
39. Ketzoian C, Oeninger C, Alcántaran J, et al. Estudio de la prevalencia de la esclerosis múltiple en Uruguay. Acta Neurol Col 1999;15:6.
40. Alvarez G, Castillo J, Cárdenas M, et al. Multiple sclerosis in Chile. Acta Neurol Scand 1992; 85: 1-4.
41. Barahona J, Montero A, Flores A. Multiple sclerosis in Chile. Arq Neuropsiquiatr 2004:62: 11.
42. Sánchez JL, Aguirre C, Arcos OM, et. al. Prevalencia de la esclerosis múltiple en Colombia. Rev Neurol 2000;31:1101-1103.
43. Cabré P, Signate A, Olindo S, et al. Role of return migration in the emergence of multiple sclerosis in the French West Indies. Brain 2005;128:2899-2910.
44. Barnett MH, Williams DB, Day S, et al. Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year study. J Neurol Sci 2003;213:1-6.
45. van der Mei IA, et al. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 2001;20:168-174.
46. Poser CM. Viking voyages: the origin of multiple sclerosis? An essay in medical history. Acta Neurol Scand Suppl 1995;161:11-22.
47. Kenealy SJ, Pericak-Vance MA, Haines JL. The genetic epidemiology of multiple sclerosis. J Neuroimmunol 2003;143:7-12.
48. Alter M, Leibowitz U, Speer J. Risk of multiple sclerosis related to age of immigration to Israel. Arch Neurol 1966;15:234-237.
49. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006;59:499-503.
50. Tartas R, Ordoñez G, Rios C, Sotelo J. Varicella, ephemeral breastfeeding and eczema as risk factors for multiple sclerosis in Mexicans. Acta Neurol Scand 2002; 105: 88-94.
51. Ordoñez G, Pineda B, Garcia-Navarrete R, Sotelo J. Brief presence of varicella-zoster viral DNA in mononuclear cells during relapses of multiple sclerosis. Arch Neurol 2004;61:529-532.
52. Perez-Cesari C, Saniger MM, Sotelo J. Frequent association of multiple sclerosis with varicella and zoster. Acta Neurol Scand 2005;112:417-419.
53. Bager P, Nielsen NM, Bihrmann K, et al. Childhood infections and risk of multiple sclerosis. Brain 2004;127:2491-2497.
54. DeStefano F, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003;60:504-509.
55. Ascherio A et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001;344:327-332.
56. Sotgiu S, Pugliatti M, Sotgiu A, Sanna A, Rosati G. Does the "hygiene hypothesis" provide an explanation for the high prevalence of multiple sclerosis in Sardinia? Autoimmunity 2003;36:257-260.
57. Acheson ED, Bachrach CA, Wright FM. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation and other variables. Acta Psychiatr Scand 1960;35(Suppl 147):132.
58. Brown SJ. The role of vitamin D in multiple sclerosis. Ann Pharmacother 2006;40: May 9 [e-publication]
59. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996;93:7861- 7864.
60. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004;62:60-66.
61. Goodin D. The return of natalizumab: weighing benefit against risk. Lancet Neurol 2006; 5:375-377.
62. Langer-Gould A, Steinman L. What went wrong in the natalizumab trials? Lancet 2006; 367:1484-1485.
63. McFarland HF, Reingold SC. The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic era. Multiple Sclerosis 2005;11:669-676.
64. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116: 117-134.
65. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
66. Li DK, Li MJ, Traboulsee A, et al. The use of MRI as an outcome measure in clinical trials. Adv Neurol 2006;98:203-26.
67. Li X, Tench CR, Morgan PS, et al. 'Importance sampling' in MS: use of diffusion tensor tractography to quantify pathology related to specific impairment. J Neurol Sci 2005;237: 13-19.
68. Ravnborg M, Gronbech-Jensen M, Jonsson A. The MS Impairment Scale: a pragmatic approach to the assessment of impairment in patients with multiple sclerosis. Mult Scler 1997;3:31-42.
69. Ravnborg M, Blinkenberg M, Sellebgerg F et al. Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale. Mult Scler 2005;11:81-84.
70. Hobart J, Lamping D, Fitzpatrick R et al. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001;124:962-973.
71. Hobart JC, Riazi A, Thompson AJ, et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 2006;129:224-234.
72. Hobart J, Kalkers N, Barkhof F, et al. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. Mult Scler 2004;10:41-46.
73. Li DK, Held U, Petkau D, et al. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 2006;66:1384-1389.
74. Thall PF, Wathen JK, Bekele BN, et al. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Stat Med 2003; 22: 763-780.
75. Kapoor R. Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design. Curr Opin Neurol 2006;19:255-259.
76. Pittock SJ, Weinshenker BG, Noseworthy JH et al. Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol 2006;63:611-614.
77. Frohman EM, Havrdova E, Barkhof F, et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at time of diagnosis. Arch Neurol 2006;63:614-619.
78. Roach ES. Early multiple sclerosis. To treat or not to treat? Arch Neurol 2006;63:619.